Galectin-1-specific inhibitors as a new class of compounds to treat HIV-1 infection.


Despite significant improvements, antiretroviral therapies against HIV-1 are plagued by a high frequency of therapeutic failures that have been associated with acquisition of drug resistance. We recently reported that HIV-1 exploits a host glycan binding protein, galectin-1, to increase its attachment to host cells, thereby increasing its overall… (More)
DOI: 10.1128/AAC.05595-11

6 Figures and Tables


  • Presentations referencing similar topics